ProQR Therapeutics NV (PRQR)

4.47
-0.16(-3.46%)
After Hours
4.68
+0.21(+4.70%)
- Real-time Data
  • Volume:
    177,343
  • Bid/Ask
    4.40/4.95
  • Day's Range
    4.44 - 4.70

PRQR Overview

Prev. Close
4.47
Day's Range
4.44 - 4.7
Revenue
11.42M
Open
4.51
52 wk Range
3.4 - 7.7
EPS
-1.11
Volume
177,343
Market Cap
241.97M
Dividend (Yield)
N/A (N/A)
Average Volume (3m)
701,346
P/E Ratio
N/A
Beta
0.42
1-Year Change
-43.77%
Shares Outstanding
54,131,553
Next Earnings Date
04 May 2021
What is your sentiment on ProQR Therapeutics NV?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

ProQR Therapeutics NV Company Profile

ProQR Therapeutics NV Company Profile

Employees
154

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.